Tag: pelacarsen

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers a corporate topline announcement about a completed cardiovascular outcomes trial in a listed company’s pivotal asset. Every result-layer number below is attributed as a company statement; trial design, population, and…